Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305682 · ClinicalTrials.gov registry record · Phase 2
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 295
- Enrollment target
NCT00305682: Completed Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT00305682 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 295 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (122% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00305682, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 295 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. An umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving sirolimus and mycophenolate mofetil after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide together with total-body irradiation followed by an umbilical cord blood transplant, sirolimus, and mycophenolate mofetil works in treating patients with hematologic cancer.
Primary Outcome
Overall Survival - Number of patients alive at 1 year post transplant
Interventions
- DRUG Fludarabine
- DRUG cyclophosphamide
- BIOLOGICAL anti-thymocyte globulin
- DRUG mycophenolate mofetil
- PROCEDURE umbilical cord blood transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2005-06 |
| Est. Completion | 2019-12-12 |
| Phase | Phase 2 |
What the finished NCT00305682 record still lists
NCT00305682 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (122% higher).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00305682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00305682 about?
NCT00305682 is a clinical study titled "Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant". RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. An umbilical cord blood transplan...
What is the current status of trial NCT00305682?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2005-06. Estimated completion is 2019-12-12.
What interventions are being tested in trial NCT00305682?
The interventions under investigation include: Fludarabine (DRUG), cyclophosphamide (DRUG), anti-thymocyte globulin (BIOLOGICAL), mycophenolate mofetil (DRUG), umbilical cord blood transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00305682?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00305682's enrollment target sits among peer trials
295 189th of 2000 higher than 1,811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia